207 HIGH RISK MDS PATIENTS SUITABLE FOR ALLOGENEIC TRANSPLANT: IMPACT ON TREATMENT SELECTED (AZA OR CHEMOTHERAPY) ON OUTCOME. SINGLE EXPERIENCE CENTER | Publicación